Douglas Earl Martin

Track

Insider profile

Performance

Overall performance
1.4
Performance over holding periods
1.4
30 days 90 days 120 days
Average return -37% 8.2% 15.1%
Success rate 0% 68% 82%
Transactions
2 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Douglas Earl Martin's trades of Allogene Therapeutics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
33.25
Quantity 80,791
Value US$1,582,239
Transaction date
Proposed sale
Price
1.76
Quantity 22,900
Value US$40,215
Transaction date
Proposed sale
Price
1.71
Quantity 6,404
Value US$10,951
Transaction date
Proposed sale
Price
2.79
Quantity 28,310
Value US$78,844
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-25 2026-08-21
S Sale
93,392 +21.6%
240.99
US$730,925 		93,392 +21.6% 240.99 US$730,925
2026-08-21 2026-08-21
PrS Proposed sale
80,791
33.25
US$1,582,239 		80,791 33.25 US$1,582,239
2026-02-04 2026-02-02
S Sale
65,104 -6.8%
481.23
US$3,418,038 		65,104 -6.8% 481.23 US$3,418,038
2026-02-02 2026-02-02
PrS Proposed sale
22,900
1.76
US$40,215 		22,900 1.76 US$40,215
2025-02-05 2025-02-03
S Sale
6,404 -1.1%
1.71
US$10,951 		6,404 -1.1% 1.71 US$10,951
2025-02-03 2025-02-03
PrS Proposed sale
6,404
1.71
US$10,951 		6,404 1.71 US$10,951
2024-08-21 2024-08-21
PrS Proposed sale
28,310
2.79
US$78,844 		28,310 2.79 US$78,844